Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Interferon-induced HERC5 Inhibits Ebola Virus Particle Production and Is Antagonized by Ebola Glycoprotein

Version 1 : Received: 29 April 2021 / Approved: 30 April 2021 / Online: 30 April 2021 (15:44:44 CEST)

How to cite: Hunt, N.R.; Paparisto, E.; Labach, D.S.; Coleman, M.D.; Di Gravio, E.J.; Dodge, M.J.; Côté, M.; Müller, A.; Hoenen, T.; Barr, S.D. Interferon-induced HERC5 Inhibits Ebola Virus Particle Production and Is Antagonized by Ebola Glycoprotein. Preprints 2021, 2021040796 (doi: 10.20944/preprints202104.0796.v1). Hunt, N.R.; Paparisto, E.; Labach, D.S.; Coleman, M.D.; Di Gravio, E.J.; Dodge, M.J.; Côté, M.; Müller, A.; Hoenen, T.; Barr, S.D. Interferon-induced HERC5 Inhibits Ebola Virus Particle Production and Is Antagonized by Ebola Glycoprotein. Preprints 2021, 2021040796 (doi: 10.20944/preprints202104.0796.v1).

Abstract

Survival following Ebola virus (EBOV) infection correlates with the ability to mount an early and robust interferon (IFN) response. The host IFN-induced proteins that contribute to controlling EBOV replication are not fully known. Among the top genes with the strongest early increases in expression after infection in vivo is IFN-induced HERC5. Using a transcription- and replication-competent VLP system, we showed that HERC5 inhibits EBOV virus-like particle (VLP) replication by depleting EBOV mRNAs. The HERC5 RCC1-like domain was necessary and sufficient for this inhibition and did not require zinc finger antiviral protein (ZAP). Moreover, we showed that EBOV (Zaire) glycoprotein (GP) but not Marburg virus GP antagonized HERC5 early during infection. Our data identifies a novel ‘protagonist-antagonistic’ relationship between HERC5 and GP in the early stages of EBOV infection that could be exploited for the development of novel antiviral therapeutics.

Subject Areas

Ebola Virus, Marburg Virus, HERC5, Antiviral, Interferon

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.